Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the efficacy, safety, and tolerability of empagliflozin in patients with type 2 diabetes and hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 825) with type 2 diabetes and hypertension (mean seated systolic blood pressure [SBP] 130–159 mmHg and diastolic blood pressure [DBP] 80–99 mmHg) were randomized (double blind) to 10 mg or 25 mg empagliflozin or placebo once daily for 12 weeks. RESULTS: At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP (ambulatory blood pressure monitoring [ABPM]) was −3.44 mmHg (95% CI −4.78, −2.09) with 10 mg empagliflozin and −4.16 mmHg (−5.50, −2.83) with 25 mg empagliflozin (both P < 0.001). At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h DBP (ABPM) was −1.36 mmHg (95% CI −2.15, −0.56) with 10 mg empagliflozin and −1.72 mmHg (95% CI −2.51, −0.93) with 25 mg empagliflozin (both P < 0.001). Changes in office BP were consistent with ABPM. Adjusted mean difference versus placebo in change from baseline in HbA1c at week 12 was −0.62% (95% CI −0.72, −0.52) (−6.8 mmol/mol [95% CI −7.9, −5.7]) with 10 mg empagliflozin and −0.65% (95% CI −0.75, −0.55) (−7.1 mmol/mol [95% CI −8.2, −6.0]) with 25 mg empagliflozin (both P < 0.001). Empagliflozin was well tolerated. One patient on placebo and one patient on 10 mg empagliflozin reported events consistent with volume depletion. CONCLUSIONS: Empagliflozin was associated with significant and clinically meaningful reductions in BP and HbA1c versus placebo and was well tolerated in patients with type 2 diabetes and hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EMPA-REG BP trial, empagliflozin reduced mean 24 hour ambulatory systolic BP by approximately 3-4 mmHg after 12 weeks, 16 with consistent reductions irrespective of the number of background BP lowering drugs.17”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [16]
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 6,090
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728 · cited 1×
“Randomized controlled trials have shown reductions in major cardiovascular events when SBP was lowered to ,150 mmHg and DBP was lowered to # 85 mmHg in patients with diabetes (23,24).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Cited by
Items 101–200 of 505
Pathophysiological Links Between Diabetes and Blood Pressure
Libianto, R., Batu, D., MacIsaac, R. J., Cooper, M. E., & Ekinci, E. I. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.01.010 · Cited by 67
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 66
Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Empagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2014) · Drugs · doi:10.1007/s40265-014-0298-1 · Cited by 64
“for 12 weeks provided significant and clinically relevant improvements in HbA1c levels and 24-h SBP compared with placebo (n = 271) [49].”
BackgroundMethodInfluentialLaffel, L. M., Tamborlane, W. V., Yver, A., Simons, G., Wu, J. T., Nock, V., HOBSON, D., Hughan, K. S., Kaspers, S., & Marquard, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13629 · Cited by 64
Kohler, S., Kaspers, S., Salsali, A., Zeller, C., & Woerle, H. J. (2018) · Diabetes Care · doi:10.2337/dc17-1525 · Cited by 58
Self-citationHarris, S. T., Patorno, E., Zhuo, M., Kim, S. C., & Paik, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0529 · Cited by 59
Yip, A. S. Y., Leong, S., Teo, Y. H., Teo, Y. N., Syn, N. L. X., See, R. M., Wee, C. F., Chong, E. Y., Lee, C., Chan, M. Y., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221083509 · Cited by 62
Ramirez, A. J., Sanchez, M. J., & Sanchez, R. A. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001907 · Cited by 61
The renal effects of SGLT2 inhibitors and a mini-review of the literature
Andrianesis, V., Glykofridi, S., & Doupis, J. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816676239 · Cited by 61
“72 mmHg on 25 mg empagliflozin versus placebo; therefore empagliflozin significantly reduces not only HbA1c but also BP [Tikkanen et al. 2015].”
BackgroundRisks vs Benefits for SGLT2 Inhibitor Medications.
Pittampalli, S., Upadyayula, S., Mekala, H. M., & Lippmann, S. (2018) · Europe PMC (PubMed Central) · Cited by 60
Sugizaki, T., Zhu, S., Guo, G., Matsumoto, A., Zhao, J., Endo, M., Horiguchi, H., Morinaga, J., Tian, Z., Kadomatsu, T., et al. (2017) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-017-0012-0 · Cited by 56
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
“, 2015 [60] Phase 3 study Empaglifozin 10 or 25 mg 825 patients 14 weeks With 10 mg: - non-significant changes With 25 mg: - ↑ LDL - ↓ total cholesterol - non-significant changes in HDL and triglycerides”
BackgroundGoerg, J., Sommerfeld, M., Greiner, B., Lauer, D., Seckin, Y., Kulikov, A. N., Ivkin, D. Y., Kintscher, U., Okovityi, S. V., & Kaschina, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115437 · Cited by 58
“Several favorable effects of SGLT2 inhibitors such as increased diuresis [24], decreased arterial stiffness [25], weight and blood pressure reduction [1,26], and other cardiac benefits [27] contribute to positive outcomes in heart failure.”
BackgroundRahman, A., Fujisawa, Y., Nakano, D., Hitomi, H., & Nishiyama, A. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12725 · Cited by 52
Diabetes mellitus and hypertension: a dual threat
Oktay, A. A., Aktürk, H. K., & Jahangir, E. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000297 · Cited by 55
Mechanisms linking empagliflozin to cardiovascular and renal protection
Filardi, P. P., Avogaro, A., Bonora, E., Colivicchi, F., Fioretto, P., Maggioni, A. P., Sesti, G., & Ferrannini, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.089 · Cited by 55
Are SGLT2 Inhibitors New Hypertension Drugs?
Kario, K., Ferdinand, K. C., & Vongpatanasin, W. (2021) · Circulation · doi:10.1161/circulationaha.121.053709 · Cited by 55
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Scheen, A. J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.09.016 · Cited by 54
Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
Kinduryte, O., Clark, D., Zwiener, I., Kaspers, S., Lee, J., & Iliev, H. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01329-7 · Cited by 54
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling
Salah, H. M., Verma, S., Santos‐Gallego, C. G., Bhatt, A. S., Vaduganathan, M., Khan, M. S., Lópes, R. D., Alaref, S. J., McGuire, D. K., & Fudim, M. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10220-5 · Cited by 54
SGLT2 Inhibitors: The Latest “New Kids on the Block”!
Cefalu, W. T., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc14-3048 · Cited by 54
Böhm, M., Anker, S. D., Mahfoud, F., Lauder, L., Filippatos, G. S., Ferreira, J. P., Pocock, S., Brueckmann, M., Saloustros, I. G., Schueler, E., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac693 · Cited by 53
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management
Katsiki, N., Mikhailidis, D. P., & Theodorakis, M. J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612823666170113152742 · Cited by 52
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 48
Salsali, A., Kim, G.-H., Woerle, H. J., Broedl, U. C., & Hantel, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12734 · Cited by 51
Self-citationScheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 51
Rahman, A., Hitomi, H., & Nishiyama, A. (2017) · Hypertension Research · doi:10.1038/hr.2016.193 · Cited by 50
Chilton, R., Tikkanen, I., Hehnke, U., Woerle, H. J., & Johansen, O. E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12962 · Cited by 47
“In the EMPA-REG BP trial, treatment with empagliflozin 10 or 25 mg qd for 12 weeks significantly reduced SBP and DBP compared with placebo in patients with T2DM and hypertension.(9) In this post-hoc subgroup analysis, we have shown that treatment with empagliflozin significantly reduced SBP compared with placebo in di…”
MethodResultSelf-citationVukadinović, D., Abdin, A., Anker, S. D., Rosano, G. M. C., Mahfoud, F., Packer, M., Butler, J., & Böhm, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2584 · Cited by 49
Managing hypertension in type 2 diabetes mellitus
Horr, S. E., & Nissen, S. E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.001 · Cited by 49
Zhang, Y., Han, S., Sun, X., Wang, S., Wang, H., Liu, X., Chen, L., & Xia, L. (2018) · Medicine · doi:10.1097/md.0000000000012843 · Cited by 48
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis
Kang, Y.-X., Zhan, F., He, M., Liu, Z., & Song, X. (2020) · Vascular Pharmacology · doi:10.1016/j.vph.2020.106779 · Cited by 47
Dey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 47
Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1201073 · Cited by 47
“It should be mentioned that, despite the decrease in BP, SGLT2 inhibitors do not increase heart rate [1,4].”
Backgroundde Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 46
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 46
Targeting the vasculature in cardiometabolic disease
Boutagy, N. E., Singh, A. K., & Sessa, W. C. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148556 · Cited by 46
“Together, these studies indicate that targeting ANGPTL4 in a tissue-specific manner can improve cardiometabolic health in rodent models of atherosclerosis and T2D.”
BackgroundInfluentialLi, C. X., Liu, L. Y., Zhang, C. X., Geng, X. H., Gu, S. M., Wang, Y. Q., Liu, H., Xie, Q., & Liang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238399 · Cited by 46
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension
Tikkanen, I., Chilton, R., & Johansen, O. E. (2016) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000199 · Cited by 40
Self-citationGüler, E., Hazar‐Yavuz, A. N., Tatar, E., Haidari, M. M., Ozcan, G. S., Duruksu, G., Graça, M. P. F., Kalaskar, D. M., Gündüz, O., & Çam, M. E. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122716 · Cited by 44
Effects of Sodium Glucose Cotransporter-2 Inhibitors on Serum Uric Acid in Type 2 Diabetes Mellitus
Ahmadieh, H., & Azar, S. T. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0070 · Cited by 44
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Effects of sodium glucose co-transporter 2 inhibitors on the kidney
de Albuquerque Rocha, N., Neeland, I. J., McCullough, P. A., Toto, R. D., & McGuire, D. K. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783756 · Cited by 41
Kario, K., Hoshide, S., Okawara, Y., Tomitani, N., Yamauchi, K., Ohbayashi, H., Itabashi, N., Matsumoto, Y., & Kanegae, H. (2018) · The Journal of Clinical Hypertension · doi:10.1111/jch.13367 · Cited by 42
Brunton, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12675 · Cited by 43
Akbari, A., Rafiee, M., Sathyapalan, T., & Sahebkar, A. (2022) · Journal of Diabetes Research · doi:10.1155/2022/7520632 · Cited by 42
Liakos, A., Lambadiari, V., Bargiota, Α., Kitsios, K., Avramidis, I., Kotsa, K., Gerou, S., Boura, P., Tentolouris, N., Dimitriadis, G., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13541 · Cited by 42
Buttice, L., Ghani, M., Suthakar, J., Gnanalingham, S., Carande, E. J., Kennedy, B. W. C., Pitcher, A., Gamble, J. H. P., Ahmad, M., Lewis, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15586 · Cited by 41
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
Sarafidis, P. A., Lazaridis, A. A., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.209 · Cited by 41
Yabe, D., Yasui, A., Ji, L., Lee, M., Ronald, C. W., Chang, T., Okamura, T., Zeller, C., Kaspers, S., Lee, J., et al. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12910 · Cited by 41
Self-citationJiang, Y., Yang, P., Fu, L., Sun, L., Shen, W., & Wu, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.802992 · Cited by 40
“5mg, 5mg, 10mg Placebo Glimepiride 48 weeks Deaths, CV events, VD Tikkanen (56) T2DM+ hypertension 823 495 60.”
White, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 40
Kiuchi, S., Hisatake, S., Kabuki, T., Fujii, T., Oka, T., Dobashi, S., Hashimoto, H., & Ikeda, T. (2018) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2017.01069 · Cited by 39
Kinguchi, S., Wakui, H., Ito, Y., Kondo, Y., Azushima, K., Osada, U. N., Yamakawa, T., Iwamoto, T., Yutoh, J., Misumi, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0912-3 · Cited by 39
Ferreira, J. P., Fitchett, D., Ofstad, A. P., Kraus, B. J., Wanner, C., Zwiener, I., Zinman, B., Lauer, S., George, J. T., Rossignol, P., et al. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa073 · Cited by 39
“12 The BP-lowering effect of empagliflozin was retained in patients who were receiving 1 or multiple antihypertensive medications.”
BackgroundXu, L., Li, Y., Lang, J., Xia, P., Zhao, X., Wang, L., Yang, Y. P., & Chen, L. (2017) · PeerJ · doi:10.7717/peerj.3405 · Cited by 39
“In addition to glycemic control, SGLT2 inhibitors lower blood pressure, control body weight, and reduce cardiovascular mortality in type 2 diabetic patients with high cardiovascular risk (Baker et al., 2014; Matthaei et al., 2015; Tikkanen et al., 2015; Wilding et al., 2015; Zinman et al., 2015b).”
BackgroundInfluentialClinical features and therapeutic perspectives on hypertension in diabetics
Katayama, S., Hatano, M., & Issiki, M. (2018) · Hypertension Research · doi:10.1038/s41440-017-0001-5 · Cited by 39
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Xia, C. Q., Goud, A., D’Souza, J., Dahagam, C., Rao, X., Rajagopalan, S., & Zhong, J. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9617-4 · Cited by 37
“The improvement in cardiovascular outcomes by SGLT2 inhibitors is probably associated with their reduction effects on blood pressure [30], kidney hyperfiltration [31, 32], and body weight [33].”
BackgroundSGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure
Gupta, R., Maitz, T., Egeler, D., Mehta, A., Nyaeme, M. S., Hajra, A., Goel, A., Sreenivasan, J., Patel, N., & Aronow, W. S. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.05.005 · Cited by 37
Azizogli, A., Vitti, M., Mishra, R., Osorno, L., Heffernan, C., & Kumar, V. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300143 · Cited by 36
Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
Lovshin, J. A., & Gilbert, R. E. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0551-3 · Cited by 36
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Li, H., Tse, Y.-K., Chandramouli, C., Hon, N. W. L., Cheung, C., Lam, L.-Y., Wu, M., Huang, J.-Y., Yu, S.-Y., Leung, K. L. C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac558 · Cited by 36
Impact of empagliflozin in patients with diabetes and heart failure
Pham, D. D., Rocha, N. D. A., McGuire, D. K., & Neeland, I. J. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.07.008 · Cited by 35
“72 mmHg reduction in diastolic blood pressure.(28) In another study also demonstrating blood pressure effects, patients with type 1 diabetes taking empagliflozin Pham et al.”
BackgroundDandona, P., & Chaudhuri, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12937 · Cited by 35
Pinto, L. C. F., Rados, D. R. V., Remonti, L. R., Viana, M. V., Leitão, C. B., & Gross, J. L. (2022) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000440 · Cited by 34
Cheng, L., Fu, Q., Zhou, L., Fan, Y., Liu, F., Fan, Y., Zhang, X., Lin, W., & Wu, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-07395-x · Cited by 34
SGLT2 inhibitors as a novel senotherapeutic approach
Yeşilyurt, Z. E., Qi, C., Wang, Y.-C., Simm, A., Deelen, L., Gasim, A. H. A., Lewis, F., & Ellison, G. M. (2025) · npj Aging · doi:10.1038/s41514-025-00227-y · Cited by 33
D’Marco, L., Morillo, V., Górriz, J. L., Suarez, M., Nava, M., Ortega, Á., Parra, H., Villasmil, N., Rojas, J., & Bermúdez, V. (2021) · Journal of Diabetes Research · doi:10.1155/2021/9032378 · Cited by 33
“However, the mechanisms responsible for these beneficial effects are not completely understood yet; several hypotheses have been debated including effects on diuresis/natriuresis [38], blood pressure (BP) [39], cardiac energetic metabolism [40], the inhibition of the Na+/H+ antiporter [41], and antiinflammatory effect…”
BackgroundTargeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
Herat, L. Y., Matthews, J. R., Azzam, O., Schlaich, M. P., & Matthews, V. B. (2022) · Current Hypertension Reports · doi:10.1007/s11906-022-01170-z · Cited by 33
Kashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 33
Latest hypertension research to inform clinical practice in Asia
Kario, K., Mogi, M., & Hoshide, S. (2022) · Hypertension Research · doi:10.1038/s41440-022-00874-8 · Cited by 32
“The Japanese SGLT2 inhibitor and Angiotensin Receptor Blocker Combination Therapy in Patients With Diabetes and Uncontrolled Nocturnal Hypertension (SACRA) study [71], the EMPA-REG BP trial [72], the LUSCAR study [73], the Y-AIDA trial [74], other studies with dapagliflozin and empagliflozin [75, 76], and a post-hoc a…”
ResultRong, X., Li, X., Gou, Q., Liu, K., & Chen, X. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120953625 · Cited by 32
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment.
Plodkowski, R. A., McGarvey, M. E., Huribal, H. M., Reisinger‐Kindle, K., Kramer, B., Solomon, M., & Nguyen, Q. T. (2015) · Europe PMC (PubMed Central) · Cited by 32
Cintra, R. M. R., Moura, F. A., de Carvalho, L. S. F., Barreto, J., Tambascia, M. A., Pecoits‐Filho, R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.70 · Cited by 32
Sharif, S., Bashir, R., Adnan, A., Mansoor, S., Ahmad, I., Rashid, A., & Tahir, M. S. (2020) · Chromatographia · doi:10.1007/s10337-020-03962-4 · Cited by 32
The Effects of SGLT2 Inhibitors on Blood Pressure and Other Cardiometabolic Risk Factors
Katsimardou, A., Theofilis, P., Vordoni, A., Doumas, M. N., & Kalaitzidis, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212384 · Cited by 31
“…a reduction in SBP by 4.28 (95% CI: −6.54 to −2.02) mmHg. empagliflozin − 1.72 mmHg, 95% CI: − 2.51 to − 0.93 for empagliflozin 25 mg) was observed [26 Similarly, in a phase 3 double-blind, placebo-controlled study, which enrolled patients 311 centers in 16 countries, treatment with 10 mg of…”
InfluentialDeerochanawong, C., Chan, S. P., Matawaran, B. J., Sheu, W. H., Chan, J. C. N., Man, N. H., Suastika, K., Khoo, C. M., Yoon, K., Luk, A. O. Y., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13819 · Cited by 31
“SGLT-2 inhibitors reduce systolic BP by ~3 to 5 mmHg and diastolic BP by ~2 to 3 mmHg,(98) with similar findings for 24-hour systolic and diastolic BP and pulse pressure.(99,100) In Asian patients with T2DM, similar reductions in systolic and diastolic BP have been reported (range: SBP, −1.”
BackgroundBexagliflozin for type 2 diabetes: an overview of the data
Azzam, O., Carnagarin, R., Lugo‐Gavidia, L. M., Nolde, J. M., Matthews, V. B., & Schlaich, M. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1959915 · Cited by 31
Vaziri, Z., Saleki, K., Aram, C., Alijanizadeh, P., Pourahmad, R., Azadmehr, A., & Ziaei, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115686 · Cited by 31
Zhao, D., Liu, H., & Dong, P. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-018-0134-2 · Cited by 31
Kimura, T., Nakamura, K., Miyoshi, T., Yoshida, M., Akazawa, K., Saito, Y., Akagi, S., Ohno, Y., Kondo, M., Miura, D., et al. (2019) · International Heart Journal · doi:10.1536/ihj.18-392 · Cited by 31
Rong, X., Zhu, Y., Bo, W., Liu, K., Li, X., Gou, Q., & Chen, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.973129 · Cited by 30
Gordin, D., & Groop, P. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816636894 · Cited by 31
“Notably, the SGLT2inhibitor empagliflozin given to patients with T2D was shown to reduce both blood pressure and arterial stiffness.(44,45) These data may to some extent explain why empagliflozin is the first compound to conclusively reduce cardiovascular morbidity and mortality as shown by the EMPA-REG Outcome Study.”
BackgroundShao, S., Chang, K., Lin, S., Chang, S., Hung, M., Chan, Y., & Lai, E. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01406-3 · Cited by 29
SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
Pandey, J., & Tamrakar, A. K. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1612879 · Cited by 29
“demonstrated the decrease in blood pressure in type 1 diabetes patients [73].”
BackgroundMa, J., Huang, X., Wang, N., Li, X., Bao, Y., Wang, T., & Hao, H. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.113004 · Cited by 29
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C., Bramlage, P., Schiffer, M., Achenbach, S. S., & Schmieder, R. E. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13622 · Cited by 29
“After 6 months treatment with tofogliflozin, an improved arterial stiffness was observed in patients with type 2 diabetes.(30) Other research groups analysed changes in BP and arterial stiffness after SGLT2 inhibition mainly in patients with type 2 diabetes and type 1 diabetes.”
BackgroundRole of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
Solini, A. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0856-y · Cited by 28
Shestakova, M. V., Wilding, J. P. H., Wilpshaar, W., Tretter, R., Orlova, V. L., & Verbovoy, A. F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.018 · Cited by 28
“[29] Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, et al.”
BackgroundCardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
See, R. M., Teo, Y. N., Teo, Y. H., Syn, N. L. X., Yip, A. S. Y., Leong, S., Wee, C. F., Cheong, A. J. Y., Lee, C., Chan, M. Y., et al. (2021) · Pharmacology · doi:10.1159/000520903 · Cited by 27
Feitosa, M. P. M., Lima, E. G., Abizaid, A., Mehran, R., Lopes, N. H. M., Ramos, T. D. A. F., Hideo‐Kajita, A., Filho, R. K., & Junior, C. V. S. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01107-9 · Cited by 27
Diabetes and Hypertension: Clinical Update
Khangura, D., Kurukulasuriya, L. R., Whaley‐Connell, A. T., & Sowers, J. R. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpy025 · Cited by 27
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Metadata
- Authors
- Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J.
- Affiliations
- Helsinki University Hospital (FI)
- Boehringer Ingelheim (Finland) (FI)
- Boehringer Ingelheim (Germany) (DE)
- inVentiv Health Clinical (CA)
- Corresponding author
- Tikkanen, Ilkka
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-30
- Volume
- 38
- Issue
- 3
- Pages
- 420-428
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2138173919
- Cited by
- 468
- References
- 35
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 27 · 2023: 41 · 2022: 39 · 2021: 38 · 2020: 41 · 2019: 50 · 2018: 44 · 2017: 52 · 2016: 53 · 2015: 31 · 2014: 3
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, type 2 diabetes, hypertension, blood pressure reduction, SGLT2 inhibitors, ambulatory blood pressure monitoring, glycemic control, HbA1c, tolerability, adverse events, dose comparison, antihypertensive therapy, renin-angiotensin system blockade
- MeSH terms
- Analysis of Variance, Antihypertensive Agents, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Administration Schedule, Female, Glucosides, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Weight Loss, Treatment Outcome, Blood Pressure Monitoring, Ambulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.